93 related articles for article (PubMed ID: 9769394)
1. In vitro carboplatin-mesna interaction in aqueous solution, human plasma and urine.
Obrocea MM; Nassim MA; Molepo MJ; Shirazi FH; Gallant G; Dulude H; Vincent MD; Stewart DJ; Goel R
Oncol Rep; 1998; 5(6):1493-8. PubMed ID: 9769394
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
Smith PF; Booker BM; Creaven P; Perez R; Pendyala L
J Clin Pharmacol; 2003 Dec; 43(12):1324-8. PubMed ID: 14615468
[TBL] [Abstract][Full Text] [Related]
3. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
[TBL] [Abstract][Full Text] [Related]
4. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxiplatin and carboplatin.
Oprea A; Bazzazi H; Kangarloo B; Wolff JE
Anticancer Res; 2001; 21(2A):1225-9. PubMed ID: 11396168
[TBL] [Abstract][Full Text] [Related]
5. Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection.
Verschraagen M; Zwiers TH; de Koning PE; Welink J; van der Vijgh WJ
J Chromatogr B Biomed Sci Appl; 2001 Apr; 753(2):293-302. PubMed ID: 11334343
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
7. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.
Verschraagen M; Boven E; Zegers I; Hausheer FH; Van der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Jun; 51(6):525-9. PubMed ID: 12750838
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
10. Liquid chromatographic analysis of mesna and dimesna in plasma and urine of patients treated with mesna.
el-Yazigi A; Yusuf A; al-Rawithi S
Ther Drug Monit; 1995 Apr; 17(2):153-8. PubMed ID: 7624904
[TBL] [Abstract][Full Text] [Related]
11. Mesna inactivates platinum agents in vitro.
Wolff JE; Egeler RM; Anderson R; Ujack E; Iceton S; Coppes MJ
Anticancer Res; 1998; 18(6A):4077-81. PubMed ID: 9891448
[TBL] [Abstract][Full Text] [Related]
12. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
[TBL] [Abstract][Full Text] [Related]
13. Estimation of mesna and dimesna in plasma and urine by high-performance liquid chromatography with electrochemical detection.
James CA; Rogers HJ
J Chromatogr; 1986 Oct; 382():394-8. PubMed ID: 3097045
[No Abstract] [Full Text] [Related]
14. In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.
Gaver RC; George AM; Deeb G
Cancer Chemother Pharmacol; 1987; 20(4):271-6. PubMed ID: 3319277
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
16. The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG.
Verschraagen M; Kedde MA; Hausheer FH; Van Der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Jun; 51(6):499-504. PubMed ID: 12715205
[TBL] [Abstract][Full Text] [Related]
17. High performance liquid chromatography analysis of MESNA (2-mercaptoethane sulfonate) in biological samples using fluorescence detection.
Mare S; Penugonda S; Ercal N
Biomed Chromatogr; 2005 Jan; 19(1):80-6. PubMed ID: 15372507
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of carboplatin.
van der Vijgh WJ
Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
[TBL] [Abstract][Full Text] [Related]
19. Experimental studies on the pharmacokinetics and nephrotoxicity of carboplatin (cis-diammine-1, 1-cyclobutane dicarboxylate platinum II) in rats.
Ueda T; Yasumasu T; Uozumi J
J Toxicol Sci; 1991 Aug; 16(3):101-9. PubMed ID: 1942134
[TBL] [Abstract][Full Text] [Related]
20. Oral bioavailability of mesna tablets.
Stofer-Vogel B; Cerny T; Borner M; Lauterburg BH
Cancer Chemother Pharmacol; 1993; 32(1):78-81. PubMed ID: 8462128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]